Mike Pishvaian, MD, PhD
Associate Professor, Gastrointestinal Oncologist and Co-Director, Clinical Research at the Sheikh Ahmed
Bin Zayed Al Nahyan Center for Pancreatic Cancer
University of Texas, MD Anderson Cancer Center
Dr. Pishvaian is an Associate Professor, gastrointestinal oncologist, and Co-director for Clinical Research at the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research at the University of Texas, MD Anderson Cancer Center.
Dr. Pishvaian is an MD and a PhD in Tumor Biology, and earned both degrees at Georgetown in 2001. He remained at Georgetown after graduation, completing his medical residency in 2004, then his fellowship in Hematology/Oncology in 2007. He served on the faculty at Georgetown until moving to MD Anderson in 2019.
Dr. Pishvaian is a translational oncologist, focused on providing novel therapy for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer. His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Dr. Pishvaian is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy.